Evidence map›Paper›PMID 33850691›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Nitric Oxide to Fight Viral Infections.

Fabio Lisi, Alexander N Zelikin, Rona Chandrawati

Open access · goldAbstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health.International journal of molecular sciences · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Deciphering the immunomodulatory mechanisms ofFrontiers in cell and developmental biology · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Fabio LisiSchool of Chemical Engineering and Australian Centre for NanoMedicine (ACN) The University of New South Wales (UNSW Sydney) Sydney NSW 2052 Australia.ORCID 0000-0003-3597-596X
Alexander N ZelikinDepartment of Chemistry and iNANO Interdisciplinary Nanoscience Center Aarhus University Aarhus 8000 Denmark.ORCID 0000-0002-9864-321X
Rona ChandrawatiSchool of Chemical Engineering and Australian Centre for NanoMedicine (ACN) The University of New South Wales (UNSW Sydney) Sydney NSW 2052 Australia.ORCID 0000-0002-9780-8844
UNSW Sydney · AUAarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that has quickly and deeply affected the world, with over 60 million confirmed cases. There has been a great effort worldwide to contain the virus and to search for an effective treatment for patients who become critically ill with COVID-19. A promising therapeutic compound currently undergoing clinical trials for COVID-19 is nitric oxide (NO), which is a free radical that has been previously reported to inhibit the replication of several DNA and RNA viruses, including coronaviruses. Although NO has potent antiviral activity, it has a complex role in the immunological host responses to viral infections, i.e., it can be essential for pathogen control or detrimental for the host, depending on its concentration and the type of virus. In this Essay, the antiviral role of NO against SARS-CoV, SARS-CoV-2, and other human viruses is highlighted, current development of NO-based therapies used in the clinic is summarized, existing challenges are discussed and possible further developments of NO to fight viral infections are suggested.

Indexed as

Antiviral AgentsClinical Trials as TopicCOVID-19COVID-19 Drug TreatmentHumansNitric OxideNitric Oxide Synthase Type IISARS-CoV-2Virus DiseasesVirus ReplicationAntiviral AgentsNitric OxideNitric Oxide Synthase Type IIcoronavirusCOVID‐19nitric oxideviral infectionsvirus

Identifiers

PMID33850691
PMCPMC7995026
OpenAlexW3126857052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.